Blaine Davis's most recent trade in Cartesian Therapeutics Inc was a trade of 10,591 Common Stock done at an average price of $6.8 . Disclosure was reported to the exchange on Jan. 6, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cartesian Therapeutics Inc | Blaine Davis | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.82 per share. | 06 Jan 2026 | 10,591 | 121,220 (0%) | 0% | 6.8 | 72,227 | Common Stock |
| Cartesian Therapeutics Inc | Blaine Davis | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 109,000 | 109,000 | - | - | Employee Stock Option (right to buy) | |
| Cartesian Therapeutics Inc | Blaine Davis | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 37,000 | 131,811 (0%) | 0% | 0 | Common Stock | |
| Cartesian Therapeutics Inc | Blaine Davis | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.83 per share. | 03 Jan 2025 | 4,028 | 94,811 (0%) | 0% | 16.8 | 67,800 | Common Stock |
| Cartesian Therapeutics Inc | Blaine Davis | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.72 per share. | 03 Jan 2025 | 3,961 | 98,839 (0%) | 0% | 16.7 | 66,235 | Common Stock |
| Cartesian Therapeutics Inc | Blaine Davis | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 64,600 | 64,600 | - | - | Employee Stock Option (right to buy) | |
| Cartesian Therapeutics Inc | Blaine Davis | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 22,000 | 102,800 (0%) | 0% | 0 | Common Stock | |
| Selecta Biosciences Inc | Davis Blaine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 3,110,000 | 3,110,000 | - | - | Employee Stock Option (right to buy) | |
| Selecta Biosciences Inc | Davis Blaine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 2,424,000 | 2,424,000 (2%) | 2% | 0 | Common Stock | |
| Selecta Biosciences Inc | Blaine Davis | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Nov 2022 | 1,250,000 | 1,250,000 | - | - | Employee Stock Option (right to buy) | |
| Protara Therapeutics Inc | Blaine Davis | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.13 per share. | 15 Jul 2022 | 5,081 | 20,662 (0%) | 0% | 3.1 | 15,904 | Common Stock |
| Protara Therapeutics Inc | Blaine Davis | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 84,800 | 84,800 | - | - | Stock Option (Right to Buy) | |
| Protara Therapeutics Inc | Blaine Davis | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 14,100 | 15,581 (0%) | 0% | 0 | Common Stock |